Stocks
Funds
Screener
Sectors
Watchlists
PLUR

PLUR - Pluri Inc Stock Price, Fair Value and News

$3.32+0.02 (+0.61%)
Market Closed

4/100

PLUR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

4/100

PLUR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.66

Target 3M

$2.99

Target 6M

$2.82

PLUR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PLUR Price Action

Last 7 days

10.3%

Last 30 days

8.5%

Last 90 days

-14.6%

Trailing 12 Months

-25.7%

PLUR RSI Chart

PLUR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PLUR Valuation

Market Cap

30.7M

Price/Earnings (Trailing)

-1.36

Price/Sales (Trailing)

23.17

EV/EBITDA

-1.06

Price/Free Cashflow

-1.46

PLUR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.66

Target 3M

$2.99

Target 6M

$2.82

PLUR Fundamentals

PLUR Revenue

Revenue (TTM)

1.3M

Rev. Growth (Yr)

-3.07%

Rev. Growth (Qtr)

-20.6%

PLUR Earnings

Earnings (TTM)

-22.6M

Earnings Growth (Yr)

0.54%

Earnings Growth (Qtr)

23.01%

PLUR Profitability

Operating Margin

42.91%

EBT Margin

-1753.77%

Return on Equity

399.34%

Return on Assets

-66.97%

Free Cashflow Yield

-68.68%

PLUR Investor Care

Shares Dilution (1Y)

66.48%

Diluted EPS (TTM)

-3.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.0M1.3M1.3M0
2024341.0K326.0K598.0K678.0K
2023789.0K287.0K322.0K357.0K
202201.2M1.8M1.3M
20210000
20200000
201953.0K54.0K106.0K79.0K
2018982.3K50.0K51.0K52.0K
20170001.9M
20162.2M2.8M00
2015379.0K379.0K996.0K1.6M
2014380.0K379.0K379.0K379.0K
2013685.0K679.0K579.0K479.0K
20120716.0K757.0K721.0K
20110000
PLUR
Pluri Inc., a bio-technology company, creates cell-based products for commercial use. The company's technology platform, a 3D cell expansion system, advances novel cell-based solutions for a range of initiatives from medicine and climate change to food scarcity, animal cruelty, and other. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
 CEO
 WEBSITEpluri-biotech.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES154

Pluri Inc Frequently Asked Questions


PLUR is the stock ticker symbol of Pluri Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Pluri Inc is 30.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PLUR's fair value in chart for subscribers.

The fair value guage provides a quick view whether PLUR is over valued or under valued. Whether Pluri Inc is cheap or expensive depends on the assumptions which impact Pluri Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLUR.

As of Wed Jan 28 2026, PLUR's PE ratio (Price to Earnings) is -1.36 and Price to Sales (PS) ratio is 23.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLUR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Pluri Inc has provided -0.263 (multiply by 100 for percentage) rate of return.